Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.54 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.54 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.54 |
| ▸ | TACR1 | P25103 | 2/20 | 0.54 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 3/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27843840 | 1.00 | F2 (0.54) | F2PRSS1PRSS2PRSS3TACR1 | |
| SCHEMBL7076149 | 0.94 | FKBP4 (0.56) | F2PRSS1PRSS2PRSS3TACR1 | |
| SCHEMBL3667052 | 0.90 | FKBP4 (0.58) | TACR1FKBP4OPRM1OPRD1OPRK1 | |
| SCHEMBL3277774 | 0.89 | FKBP4 (0.57) | TACR1FKBP4OPRM1OPRD1OPRK1 | |
| 4-Nitroaniline SCHEMBL29006907 | 0.87 | ACE (0.54) | — | |
| 4-Nitroaniline SCHEMBL29006906 | 0.87 | ACE (0.54) | — | |
| SCHEMBL9011317 | 0.87 | DPP4 (0.58) | F2PRSS1PRSS2PRSS3TACR1 | |
| SCHEMBL30608508 | 0.85 | F2 (0.47) | F2PRSS1PRSS2PRSS3TACR1 | |
| SCHEMBL6058133 | 0.85 | OPRM1 (0.56) | TACR1FKBP4OPRM1OPRD1OPRK1 | |
| SCHEMBL27824844 | 0.85 | LMNA (0.48) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835393-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20110269696-A1 | INHIBITORS OF IAPS | GENENTECH INC. (US) | 2011-11-03 | — | — | US | disclosed |
| EP-2318395-A2 | INHIBITORS OF IAP | Genentech, Inc. (US) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010017035-A2 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269696-A1 | INHIBITORS OF IAPS | XIAP, BIRC5, BIRC3 | F2 3854/4885PRSS1 103/4885PRSS2 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.